BSE Live
Apr 01, 16:00Prev. Close
859.90
Open Price
814.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 01, 15:59Prev. Close
859.80
Open Price
814.70
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
859.80 (9924)
| Profit & Loss account of Ranbaxy Laboratories (in Rs. Cr.) | Mar 14 | Dec 12 | Dec 11 | |
| 15 mths | 12 mths | 12 mths | ||
| INCOME | ||||
| Revenue From Operations [Gross] | 6,701.06 | 6,140.36 | 7,494.94 | |
| Less: Excise/Sevice Tax/Other Levies | 44.02 | 27.91 | 19.05 | |
| Revenue From Operations [Net] | 6,657.04 | 6,112.44 | 7,475.90 | |
| Total Operating Revenues | 6,864.94 | 6,303.54 | 7,799.06 | |
| Other Income | 784.82 | 257.16 | 222.66 | |
| Total Revenue | 7,649.76 | 6,560.71 | 8,021.71 | |
| EXPENSES | ||||
| Cost Of Materials Consumed | 2,065.33 | 1,528.66 | 1,784.91 | |
| Purchase Of Stock-In Trade | 982.64 | 809.00 | 636.73 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -175.12 | -49.25 | -135.72 | |
| Employee Benefit Expenses | 1,274.73 | 1,019.59 | 860.71 | |
| Finance Costs | 547.05 | 296.98 | 299.00 | |
| Depreciation And Amortisation Expenses | 280.17 | 186.16 | 274.08 | |
| Other Expenses | 3,041.84 | 2,552.62 | 3,578.38 | |
| Total Expenses | 8,016.64 | 6,343.77 | 7,298.10 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | -366.88 | 216.94 | 723.62 | |
| Exceptional Items | -481.54 | -381.23 | -3,772.29 | |
| Profit/Loss Before Tax | -848.43 | -164.28 | -3,048.67 | |
| Tax Expenses-Continued Operations | ||||
| Current Tax | 30.57 | -1.94 | -3.31 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 0.00 | 0.00 | 6.69 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 30.57 | -1.94 | 3.38 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | -879.00 | -162.34 | -3,052.05 | |
| Profit/Loss From Continuing Operations | -879.00 | -162.34 | -3,052.05 | |
| Profit/Loss For The Period | -879.00 | -162.34 | -3,052.05 | |
| OTHER ADDITIONAL INFORMATION | ||||
| EARNINGS PER SHARE | ||||
| Basic EPS (Rs.) | -21.00 | -4.00 | -72.00 | |
| Diluted EPS (Rs.) | -21.00 | -4.00 | -72.00 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||
| Imported Raw Materials | 1,021.63 | 829.46 | 918.54 | |
| Indigenous Raw Materials | 759.94 | 467.91 | 645.12 | |
| STORES, SPARES AND LOOSE TOOLS | ||||
| Imported Stores And Spares | 10.84 | 14.05 | 12.07 | |
| Indigenous Stores And Spares | 123.73 | 101.38 | 89.37 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 |
04.05.2020
Book review: ‘Bottle of Lies’ explores Ranbaxy and the unethical underbelly of Indian pharma
01.08.2019
ED raids premises of former Ranbaxy group promoters under PMLA
20.12.2016
Withdraw nod for 28 drug applications of Ranbaxy: Sun Pharma
07.03.2016
Pharma crusader Thakur takes India's drug regulators to court
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth